IE
ARQT icon

Israel Englander’s Arcutis Biotherapeutics ARQT Stock Holding History

Israel Englander’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-11,600
Closed -$61.6K – 6061
2023
Q3 		$61.6K Hold
11,600
– – ﹤0.01% 5443
2023
Q2 		$111K Buy
+11,600
New +$129K ﹤0.01% 5306

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
California State Teachers Retirement System (CalSTRS)
California State Teachers Retirement System (CalSTRS) West Sacramento, California $782B AUM 28.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Israel Englander's ARQT Position: Q2 2026 in Review

Israel Englander increased its Arcutis Biotherapeutics (ARQT) stake by 1,043% in Q2 2026, buying an estimated $12M and bringing the position to 564,072 shares worth $14.8M. The position accounts for 0.01% of the portfolio, ranked #1909.

Israel Englander first reported a position in ARQT in Q1 2020 and has held it in 21 quarters since. The position peaked at $32.2M in Q4 2024. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Israel Englander held 564,072 shares of Arcutis Biotherapeutics worth $14.8M as of Q2 2026.
  • Israel Englander bought 514,739 Arcutis Biotherapeutics shares in Q2 2026, an estimated $12M.
  • Arcutis Biotherapeutics made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1909 holding.
  • Israel Englander first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 21 quarters since.
  • Israel Englander's Arcutis Biotherapeutics position peaked at $32.2M in Q4 2024.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.